What is coming, and why it matters
MyBloodQ™ Breast
Exploring a new blood-based approach to finding breast cancer earlier.
Roughly 40% to 50% of women ages 40 to 74 have dense breasts, and dense tissue can make a mammogram harder to read.1 The question our research is asking is whether blood could one day add something alongside a mammogram, not in place of one.
MyBloodQ Breast is in development. It is not available today and it is not FDA cleared or approved.
Dense breasts and mammography
For millions of women with dense breasts, mammography can be harder to read.
You get your mammogram. You do what you are supposed to do. And a question can still stay with you afterward. Did we see everything we needed to see?
Mammography saves lives and remains the foundation of breast cancer screening. But dense breast tissue can make some cancers harder to see, and roughly 40% to 50% of women ages 40 to 74 have dense breasts.1 That does not mean screening less. It means continuing to look for additional ways to understand what may be happening.
Why earlier matters
When breast cancer is found earlier, more options can stay open.
Of women whose breast cancer is found while it is still confined to the breast, more than 99% are alive five years later. When it is not found until it has spread to distant organs, that figure is 32%.2
Five-year relative survival for invasive breast cancer, by how far it had spread at diagnosis (SEER summary stage: localized versus distant). This is general information about breast cancer. It is not a claim about MyBloodQ or MyBloodQ Breast.
Another way to look
A mammogram looks at breast tissue. MyBloodQ Breast looks at molecular patterns in blood.
A mammogram
Creates an image of breast tissue. In dense tissue, a small finding and the tissue around it can look a lot alike.
MyBloodQ Breast (in development)
Measures a broad molecular fingerprint in blood. The sample is the same small draw whether your tissue is dense or not.
MyBloodQ uses infrared light and machine learning to read a broad molecular fingerprint in a small blood sample. Most tests measure one marker, or a few. MyBloodQ evaluates the overall molecular pattern.
What we are building for
Earlier. Evaluated. Accessible.
Earlier
Our work has focused on the earliest stages of breast cancer, because that is when finding disease can leave more options open.
Evaluated in blinded studies
The algorithm was frozen before two blinded studies evaluated it. The researchers running those studies did not know which samples came from people with cancer.
Accessible
A small blood draw. Fast laboratory processing. And a commitment to making MyBloodQ Breast as broadly available as we can by controlling what it costs, because earlier detection only matters if people can actually reach it.
The research behind it
How MyBloodQ was developed and tested.
Where the work has gone, in the order it happened.
Step one
Development samples
A large research dataset of blood samples, from people who had cancer and people who did not.
Step two
Algorithm developed and frozen
Once the model was built it was fixed, so it could not be adjusted afterward to improve its own results.
Step three
Two independent blinded studies
Separate groups of coded samples, evaluated by researchers who did not know which came from people with cancer.
Now
Bringing it into the clinic
Working with clinical partners on laboratory validation, site baselines and the everyday processes a real clinic needs.
Steps one through three were research studies on stored samples. They do not establish what a clinical test would do for any one person.
We share the research figures with clinicians and scientists who can weigh them properly. We do not publish them here, on purpose.
Why Person Health exists
Disease should never be a surprise.
Chief Executive Officer
Person Health
and a cancer survivor
“I know what it feels like to wonder whether disease could have been found sooner. That is why earlier is not an abstract idea to us.”
Person Health was founded to move healthcare from reactive to proactive. From finding disease once it announces itself, to recognizing meaningful change while there is still the most to do about it. We believe the future of healthcare is earlier, more certain and more accessible, and that those three only matter together: earlier detection changes very little if people cannot reach it. That is the world we are trying to create.
Where things stand
Where MyBloodQ Breast stands today.
Today
Research use only
MyBloodQ is being used in research today, including work with clinical partners to establish baseline data. The research does not return an individual result to anyone who takes part, and it is not a test you can ask for.
Coming
MyBloodQ Breast
We are working toward MyBloodQ Breast as a clinician-ordered laboratory developed test, or LDT, subject to the remaining laboratory, validation and operational requirements. It is not available today and it is not FDA cleared or approved.
Beyond
This is just the beginning
Blood, breath, imaging and health history brought together, so that people and their clinicians can recognize meaningful change earlier. MyBloodQ Breast is the first step of a much larger idea, not the whole of it.
Where we are starting
We are beginning here in Minnesota.
The research, the laboratory and the first clinical work are all here. If MyBloodQ Breast becomes available, Minnesota is where it begins.
In the meantime, talk with your own clinician about the screening that is right for you. Everything on this page is general information, not medical advice.
Questions we hear most
What you will want to know about MyBloodQ Breast.
What is MyBloodQ Breast?
A blood test in development, designed to be ordered by a clinician, that uses infrared light and machine learning to read a broad molecular fingerprint associated with breast cancer. It is not available today and it is not FDA cleared or approved.
Why blood?
Blood contains a rich mixture of biological information. MyBloodQ uses infrared light and machine learning to read a broad molecular fingerprint across major categories of biomolecules, rather than relying on a single biomarker. A mammogram reads the structure of breast tissue, and dense tissue is what makes that harder. A blood sample is the same small draw for everyone. Whether reading blood can add something useful alongside a mammogram is exactly what the research is asking.
Why could this help find cancer earlier?
Cancer can begin changing the molecular environment of the body before a person feels symptoms and before a physical change is easy to see. MyBloodQ Breast is designed to look for those broader molecular patterns. And earlier matters for a human reason, not a technical one. Finding disease while it is still small can mean more treatment options, and potentially less intensive care.
What has the research shown?
The MyBloodQ model was developed on a large research dataset. The algorithm was then frozen and evaluated in two blinded studies. Those were research studies on stored samples, and they do not establish what a clinical test would do for any one person. That is what the clinical work now underway is for.
Does this replace my mammogram?
No. Mammography is the foundation of breast cancer screening and nothing we are studying changes that. What we are asking is whether blood could one day add information alongside a mammogram, not in place of one. Keep the screening schedule you and your clinician have agreed on.
What would getting the test be like?
A standard blood draw, about a teaspoon or less. Your sample goes to the Person Health laboratory for analysis, and the result goes to the clinician who ordered it. Our expectation is that results would generally be returned to the ordering clinician about one business day after the sample is received, depending on laboratory volume.
How will I get the result?
Through the clinician who ordered it, who can read it alongside everything else they know about your health and talk with you about what comes next.
How accessible will it be?
MyBloodQ Breast is being designed around scalable technology, a simple blood draw and fast laboratory processing, because earlier detection matters most when people can actually reach it.
When will it be available?
We are targeting early Q4 2026, subject to completing the remaining laboratory, validation and operational requirements. That is a goal, not a promise, and it is not a reason to change the screening you and your clinician have planned. We are excited to begin here in Minnesota and expand from there.
Can I take part in the research?
Taking part is arranged only through an approved research site, not through this page. This page is not an invitation to join a study, it does not screen or enroll anyone, and it gives no one priority or early access to MyBloodQ Breast.